Anteris Technologies Global Corp. · NASDAQ:AVR
Anteris Technologies Global — Shareholder Meeting (December 2025)
57 slides from Anteris Technologies Global's shareholder meeting presentation, December 2025
Slide 1: Annual Meeting December 2025
Annual Meeting December 2025 NASDAQ: AVR | ASX: AVR
Slide 2: Disclaimer: Forward-Looking Statements
Disclaimer Forward-Looking Statements This presentation (including oral commentary that accompanies this presentation) contains forward-looking statements, including statements related to our business, products and clinical trials and studies. Any statements about our expectations, beliefs, plans, p
Slide 3: Disclaimer: Non-GAAP Financial Measures
Disclaimer Non-GAAP Financial Measures This presentation includes a discussion of our operating spend, which is an unaudited financial measure that is not based on any standardized methodology prescribed by U.S. generally accepted accounting principles (GAAP) and may be calculated differently from,
Slide 4: Leading the Field
Leading the Field
Slide 5: Slide 5
Slide 6: FY2024 Key Numbers
FY2024 Key Numbers CASH 136.1 * $70.5M * EMPLOYEES & CONTRACTORS Compared to $21.1M FTE supporting Anteris’ at Dec 31, 2023 business strategy 41.2% CAPITAL RAISED R&D COSTS IN 2024 $51.5M $125.9M Compared to $30.9M in 2023 Including IPO 66.6% All amounts are in USD Percentages reflect year-on-ye
Slide 7: Key 2025 Highlights
Key 2025 Highlights 159.9 * CASH $9.1M * EMPLOYEES & CONTRACTORS Compared to $70.5M FTE supporting Anteris’ at Dec 31, 2024 business strategy 41.2% since Dec 2024 R&D COSTS* Q4 2025 Q4 2025 YTD 9 MONTHS PRIVATE PLACEMENT REGULATORY $25.2M $49.6M APPROVALS COMPARED TO $38.1M received to start the G
Slide 8: Focused R&D Expenditures Driving the Path to Approval
Focused R&D Expenditures Driving the Path to Approval Research and Development Costs ResearchR&D Driving Innovation: and Development is 76.4% of our operating spend1 • PARADIGM trial preparatory costs • Expansion of clinical field team 76.4% • Upscaling manufacturing capabilities • DurAVR® valve dev
Slide 9: Reconciliation of R&D expenditures to Operating spend
Reconciliation of R&D expenditures to Operating spend 12 months 12 months 9 months Dec 31, 2023 Dec 31, 2024 Sept 30, 2025 $M 1 $M 1 $M 2 Research & Development expense (R&D) Total R&D disclosed in Forms 10-K and 10-Q 30.9 51.5 49.6 Stock-based compensation expense related to R&D (non-cash) (2.7) (0
Slide 10: Positive FX Impact Linked to Decline in AUD
Positive FX Impact Linked to Decline in AUD 0.80 0.75 5-year average: 1 AUD = 0.68 USD YTD 2025 average: 1 AUD = 0.64 USD 0.70 0.65 0.60 0.55 Nov-2020 May-2021 Nov-2021 May-2022 Nov-2022 May-2023 Nov-2023 May-2024 Nov-2024 May-2025 Nov-2025 Source: Reserve Bank of Australia, Statistical tables, Exch
Slide 11: Positive FX Impact Linked to Decline in AUD
Positive FX Impact Linked to Decline in AUD 12.0 AUD 10.4M 10.0 USD USD 7.4M USD AUD 10.4M of expenses 8.0 7.1M • 6.7M incurred in YTD Sept 2025 converted into USD 6.7M MILLIONS 6.0 • The same AUD 10.4M using the prior 10-year average FX 4.0 rate converts into USD 7.4M 2.0 0.0 YTD Sept 2025 AUD 10-y
Slide 12: Access to Capital Has Increased With Our Data
Access to Capital Has Increased With Our Data !
Slide 13: Continued Institutional Support
Continued Institutional Support • Top shareholders continue to demonstrate strong support • Concentrated ownership among high-quality, physician-led institutional investors • Since IPO, mix of top 20 shareholders shifted to the US • Greater than 10-fold increase in liquidity (volume) since US IPO •
Slide 14: Ongoing Large Shareholder and New Institutional Support
Ongoing Large Shareholder and New Institutional Support Capital placements - funds raised • On-going support reflects confidence in the Company’s strategy and clinical progress 24% 32% 20% • Strong engagement with leading investors • 95%+ of funds raised in recent capital 76% 63% 79% placements from
Slide 15: Building a Strong, Global Workforce
Building a Strong, Global Workforce Workforce by Function Workforce by Geography Exec & Board HR, IT, Finance, Europe incl. support, 3% Investor 8% Relations, 14% Australia 26% R&D, Manufacturing, USA Regulatory & 52% 66% Medical, Marketing, PMO, 32% Employees & Contractors 159.9 FTE Gender diversit
Slide 16: Building a Strong, Diverse & Inclusive Workforce
Building a Strong, Diverse & Inclusive Workforce FTE BY FUNCTION GENDER DIVERSITY SG&A 16% 25.7 FTE Male 41% Female 134.2 FTE 59% R&D incl. manufacturing 84% September 30, 2025 Leadership and Management: 51% Male / 49% Female Employees & Contractors: 159.9 FTE 17.5% (23.8 FTE) from December 2024 *
Slide 17: Building a Strong, Diverse & Inclusive Workforce
Building a Strong, Diverse & Inclusive Workforce Norway Sweden England Albania Canada Ireland Germany Algeria Inclusive and USA France Switzerland Ukraine Collaborative Celebrating our Mexico Netherlands Spain Italy Iran China Driving Innovation Ethnic Diversity Puerto Rico India Sri Lanka Thailand
Slide 18: Setting Up a Structure For the Future
NASDAQ Setting Up a Structure For the Future
Slide 19: 2024 Re-Domiciliation and US IPO
2024 Re-Domiciliation and US IPO • Re-domiciled from Australia to US end of 2024 (Anteris Technologies Global Corp new parent) • Strong support from shareholders and option holders • Listed common stock on the Nasdaq and CDIs on the ASX • IPO raising USD 88.8M , AUD 135M (gross proceeds)
Slide 20: Liquidity Has Increased Over 1000% Since Nasdaq
Liquidity Has Increased Over 1000% Since Nasdaq Trading Volume
Slide 21: AVR Stock Price Movements
AVR Stock Price Movements $10.00 MARCH 2025 Director appointed $9.00 NOVEMBER 2025 FDA approval – PARADIGM trial JUNE 2025 $8.00 New Directors appointed DECEMBER 2024 SEPTEMBER 2025 $7.00 Nasdaq IPO ASX Listing Rule 7.1 Waiver APRIL 2025 US ‘Liberation Day’ shareholder approval $6.00 $5.00 $4.00 MAR
Slide 22: How Do We Compare to Newly Listed Small Cap MedTechs?
How Do We Compare to Newly Listed Small Cap MedTechs ? First MedTechs listed in approx 3 years
Slide 23: Stock Volatility Follows the Market
Stock Volatility Follows the Market
Slide 24: 27
27
Slide 25: A Chat with Dr Chris
A Chat with Dr Chris
Slide 26: Being Normal As a Company In This Space Was Never The Target
Being Normal As a Company In This Space Was Never The Target
Slide 27: But Bringing Patients Back To a Normal State Was
But Bringing Patients Back To a Normal State Was
Slide 28: Unpacking the Clinical Data
. See Unpacking CLINICAL the Clinical TRIAL Data a
Slide 29: DurAVR THV: A New Class of TAVR
DurAVR® THV: A New Class of TAVR Single piece, native-shaped biomimetic design built to mimic the performance of a healthy aortic valve
Slide 30: DurAVR Only THV to Demonstrate Restoration of Physiologic Laminar Flow
DurAVR® Only THV to Demonstrate Restoration of Physiologic Laminar Flow Healthy Aortic Valve Post DurAVR® THV Post DurAVR® THV FD = 10% FRR = 1% FD = 14% FRR = 4% FD = Flow Displacement, FRR = Flow Reversal Ratio Courtesy of Dr. Pankaj Garg, Norwich University Hospital (UK) Data presented at New Yor
Slide 31: Wives
Wives * ap iL <2 as
Slide 32: Slide 32
Slide 33: DurAVR THV Small Aortic Annuli Pooled Cohort
DurAVR® THV Small Aortic Annuli Pooled Cohort Symptomatic Severe Native Aortic Stenosis EMBARK DurAVR® THV US EFS EU EFS Small Valve Study DurAVR S Valve DurAVR S Valve DurAVR S Valve N=74 N=15 N=11 30-Day Follow- 30-Day Follow- 30-Day Follow- up up up N=74 N=15 N=11 Area: 346-452 mm2 DurAVR® THV Sm
Slide 34: Procedural Success Across Variety of Anatomies
Procedural Success Across Variety of Anatomies Challenging anatomies treated Technical success: 93% Severe annular calcium Extreme leaflet calcium Device success: 91% Type 1 bicuspid Extreme LVOT calcium Predictable BE placement pcrlondonvalves.com
Slide 35: Baseline Echo and CT Characteristics
Baseline Echo and CT Characteristics DurAVR® THV Baseline Echo and CT Characteristics (N=100) Aortic annulus area, mm2 404 ± 37 Aortic annulus mean diameter, mm 22.7 ± 1.0 Aortic valve area, cm2 0.8 ± 0.2 Mean transvalvular gradient, mmHg 48.1 ± 17.0 Left ventricular ejection fraction, % 58.0 ± 7.0
Slide 36: Favorable Hemodynamics Through 30 Days
Favorable Hemodynamics Through 30 Days Single-digit mean gradient and No moderate or severe 97% freedom from ≥ moderate large effective orifice area paravalvular leak prosthesis-patient mismatch DVI = 0.60 pcrlondonvalves.com
Slide 37: Hemodynamics and PPM in Small Annuli at 30 Days
Hemodynamics and PPM in Small Annuli at 30 Days Low rate of moderate or Single-digit mean gradient Large EOA severe prosthesis-patient mismatch 1,2 1,2 1,2 Error bars represent standard deviation 1. Hermann HC et al. NEMJ. 2024;390:1957-71. 2. Presented by Hermann HC SCAI 2024: SEV vs. BEV TAVR in p
Slide 38: Slide 38
Slide 39: PARADIGM Trial Design
PARADIGM Trial Design Severe Native Aortic Stenosis Failed Surgical Bioprosthesis Cohort All Comers Randomized Cohort Low Risk Randomized Cohort Valve-in-Valve Cohort Assessment for Eligibility Assessment for Eligibility Assessment for Eligibility All Risk Candidate Low Risk Candidate High-Risk Cand
Slide 40: Experience Matters
Experience Matters Clinical, Manufacturing, Launch
Slide 41: A Very Experienced Clinical Trial Team
A Very Experienced Clinical Trial Team Total culminative amount of clinical studies that current Anteris employees have been instrumental in successfully delivering: Spanning cardiovascular devices, regulatory affairs, and medical leadership across global markets 68 US Clinical and 55 EU Clinical an
Slide 42: What Else Do We Need?
What Else Do We Need?
Slide 43: We Have a World Class Experienced Team Across All Areas
We Have a World Class Experienced Team Across All Areas • VP of RA has filed for multiple approvals from one of the big MedTechs • VP Manufacturing was Head of Global TAVR manufacturing at one of the big MedTechs • VP QC was head of QC at of the Big MedTechs • Clinical Field team all come from TAVR
Slide 44: Slide 44
Slide 45: Pivot From Rx Co to MedTech - A High Risk But Necessary Strategy
Pivot From Rx Co to MedTech - A High Risk But Necessary Strategy 100 DurAVR® Patients Doctors & Patients Needs: Balloon IDE Submission Formation of Anteris’ Expandable delivery THV Medical Advisory determined with Key animal study for Board EU Reg Clearance hemodynamic EFS Submission First DurAVR® E
Slide 46: TAVR Market Opportunity Expected to Reach USD 9.9BN in 2028
TAVR Market Opportunity Expected to Reach USD 9.9BN in 2028 Underpenetrated patient population with only 15-20%1 of severe aortic stenosis cases treated today TAVR Aortic Stenosis & Valve-in-Valve Market2 Potential for further significant growth 14.0 Currently 3 industry trials in progress, anticipa
Slide 47: Value Proposition
Value Proposition Anteris has a compelling clinical Current Market Leader proposition New Entrant Edwards Lifesciences Anteris Technologies Shares outstanding Shares outstanding 580.7 million 41.2 million as of Sept 30, 2025 as of Nov 12, 2025 USD 86.67 USD 4.10 Share price(a) Share price(c) AUD 132
Slide 48: Anteris is Leading the Field
Anteris is Leading the Field
Slide 49: Slide 49
Slide 50: Slide 50
Slide 51: Board of Directors
Board of Directors John Seaberg Wayne Paterson Stephen Denaro CHAIRMAN VICE CHAIRMAN & CEO DIRECTOR Dave Roberts Greg Moss David St Denis NON-EXECUTIVE DIRECTOR NON-EXECUTIVE DIRECTOR PRESIDENT & DIRECTOR
Slide 52: Highly Experienced Leadership – Clinical, Operational, Commercial
Highly Experienced Leadership – Clinical, Operational, Commercial Wayne Paterson David St Denis VICE CHAIRMAN & CEO PRESIDENT & DIRECTOR Matthew McDonnell Dr. Chris Meduri CHIEF FINANCIAL OFFICER CHIEF MEDICAL OFFICER
Slide 53: Our Physician Advisors
; ) Our Physician Advisors
Slide 54: Our Visionary Investors
Our Visionary Investors
Slide 55: And of Course Our Patients
[] And of Course Our Patients
Slide 56: Anteris is Leading the Field
Anteris is Leading the Field
Slide 57: Slide 57
Anteris Technologies Global — Shareholder Meeting (December 2025) on 6ix